←
State of Medtech Podcast1,395 posts
State of Medtech Podcast avatar

State of Medtech Podcast

@StateofMedTech

The #1 Podcast for the Medtech Industry Hosted by @omarmkhateeb

◷ Joined December 2021▧ 1,156 Photos and videos
Omar M. Khateeb avatar
⟳ State of Medtech Podcast retweeted
Omar M. Khateeb@OmarMKhateeb·6h

Telepathy Is Here: The BCI Revolution with Matt Angle, Paradromics and Babar Khan, NEOM Investment Fund. MEDTECH TELEPATHY MAY BE CLOSER THAN MOST PEOPLE REALIZE. To understand where BCI is really heading, I spoke with @Matt_R_Angle Founder and CEO of @paradromics, and Babar Khan, Head of Technology Investments at @NEOM Investment Fund. Matt described watching a participant think words internally and seeing those thoughts appear on a computer in real time. Babar called what he witnessed telepathy. But the conversation goes much deeper than one demonstration. We talked about why BCI could evolve from a medical device for restoring speech into a completely new computing platform connecting biology with machines. We covered the tradeoffs between invasive and non-invasive BCI, why signal quality and durability matter, and why AI cannot recreate neural information that a sensor never captured. We also discussed Paradromics' funding journey, including NIH and DARPA support, the regulatory and reimbursement bottlenecks holding back frontier MedTech, and why China's coordinated approach to BCI could make neurotechnology another major global technology race. Then we got into what may be the biggest long-term opportunity: brain data and AI. If AI agents could understand human intention directly through neural signals, the keyboard, mouse, touchscreen, and even voice may eventually become less important interfaces. We also explored consumer BCI, the Middle East's potential role in the industry, regional neural decoding, and Paradromics' ambition to build an ecosystem where other researchers and companies develop applications on top of its infrastructure. The first use case is restoring lost function. The bigger question is what happens when BCI becomes a platform for everything that comes next. Episode Breakdown: 00:00 How Brain-Computer Interfaces Could Change Humanity Forever 01:22 Meet Matt Angle and Babar Khan 02:10 What Is Paradromics and How Does Its BCI Technology Work? 03:40 NEOM's Investment Strategy for Frontier Technologies 05:43 Brain-Computer Interfaces Are Moving Beyond the Laboratory 06:46 Witnessing Real-Life Telepathy Through BCI 07:34 How Brain Implants Turn Thoughts Into Words 09:16 Why BCI Is an Engineering Challenge, Not Science Fiction 11:24 Is the 510(k) Pathway Holding Back MedTech Innovation? 12:54 Market Engineering and MedTech Growth 14:36 Why MedTech Has Been Thinking Too Small 16:10 Could BCI Companies Become More Valuable Than Intuitive Surgical? 17:59 Why Brain-Computer Interfaces Are More Than Medical Devices 19:15 What Really Drives Technology Platform Valuations? 19:52 Why the MedTech Industry Needs an Investment Bubble 21:10 How Breakthrough Medical Devices Could Overcome Reimbursement Barriers 22:06 Why Brain Implant Durability Matters 23:09 Implantable vs. Wearable Brain-Computer Interfaces 23:50 The Three Pillars of BCI: Safety, Durability and Performance 26:04 Is the Human Brain the Next Great Frontier? 26:58 Intracortical Brain Implants and Clinical Evidence 27:40 Why Recording Individual Neurons Matters 28:43 How BCI Could Unlock Human Potential 29:52 From Glucose Monitoring to Continuous Brain Monitoring 31:16 Could Brain Monitoring Improve Sleep, Stress and Mental Health? 32:33 How Complex Is Brain Implant Surgery? 33:14 Inside Paradromics' Brain Implant Technology 33:54 Making Brain Implant Surgery Accessible to More Hospitals 34:34 Paradromics vs. Neuralink: Is Robotic Surgery Necessary? 35:01 Why DeepTech Entrepreneurs Should Solve One Major Problem 36:11 China's Growing Lead in BCI Commercialization 37:02 The Global Race for Brain-Computer Interface Technology 37:53 What the US Can Learn From China's BCI Strategy 39:26 How Government Policy Could Accelerate MedTech Innovation 40:46 Why Regulatory Uncertainty Holds Back DeepTech Investment 42:46 How Paradromics Secured Its Early Funding 43:07 Inside Paradromics' $180 Million Funding Journey 43:48 The $14 Million DARPA Contract and Government Funding Trap 45:19 Why FDA and CMS Alignment Matters to MedTech Investors 46:23 Why Brain Data Could Power the Next Generation of AI 46:57 How Brain-Computer Interfaces Could Transform AI Agents 49:02 Elon Musk's Neuralink and the Value of Neural Data 50:05 Why Brain Data Could Become the Next Digital Gold 50:57 Could Your Thoughts Replace Keyboards and Touchscreens? 52:42 From Restoring Disabilities to Unlocking Human Superpowers 55:44 Could Brain-Computer Interfaces Become Consumer Technology? 57:45 The Scientific Limitations of Noninvasive Ultrasound BCI 58:08 Why AI Cannot Overcome the Laws of Physics 59:59 Why Capturing Brain Signals at the Source Matters 01:00:52 The 40-Bit Problem: Why Neural Data Quality Matters 01:02:02 When Does BCI Become the Next Computing Platform? 01:02:59 The Transition From Medical Devices to Consumer Brain Implants 01:04:01 Will Healthy People Get Brain Implants Within 10 Years? 01:04:47 Why NEOM Is Investing Beyond Traditional MedTech 01:07:25 How Paradromics Plans to Follow NVIDIA's Playbook 01:08:57 Open Hardware, Patents and the Future of BCI Innovation 01:09:54 Why Partnerships Will Shape the Future of MedTech 01:11:06 Outro

1:11:48
State of Medtech Podcast avatar
State of Medtech Podcast@StateofMedTech·Nov 17

Your Pipeline Problem Might Actually Be a System Problem! Insights from @OmarMKhateeb  Episode 431: MedTech Marketing: How to Drive Medical Device Adoption & Revenue Growth!

1:02
State of Medtech Podcast avatar
State of Medtech Podcast@StateofMedTech·Nov 15

VCs Are Googling You Before the Meeting! Episode 429: MedTech Investing: What Makes Intuitive Ventures Bet $5M to $10M with Terri Burke

0:38
State of Medtech Podcast avatar
State of Medtech Podcast@StateofMedTech·Nov 15

Great Technology Means Nothing Without Market Fit! Episode 429: MedTech Investing: What Makes Intuitive Ventures Bet $5M to $10M with Terri Burke

0:52
State of Medtech Podcast avatar
State of Medtech Podcast@StateofMedTech·Nov 13

Why Founders Should Talk to VCs Before They’re Ready! Episode 429: MedTech Investing: What Makes Intuitive Ventures Bet $5M to $10M with Terri Burke

0:52
State of Medtech Podcast avatar
State of Medtech Podcast@StateofMedTech·Nov 11

VCs Don’t Invest in Technology. They Invest in Returns! Episode 429: MedTech Investing: What Makes Intuitive Ventures Bet $5M to $10M with Terri Burke

1:11
State of Medtech Podcast avatar
State of Medtech Podcast@StateofMedTech·Nov 11

Your MedTech Idea Needs More Than a Napkin Sketch! Episode 429: MedTech Investing: What Makes Intuitive Ventures Bet $5M to $10M with Terri Burke

0:51
State of Medtech Podcast avatar
State of Medtech Podcast@StateofMedTech·Nov 10

If You’ve Never Been in a Hospital, How Do You Market It? Episode 429: MedTech Investing: What Makes Intuitive Ventures Bet $5M to $10M with Terri Burke

0:42
Omar M. Khateeb avatar
⟳ State of Medtech Podcast retweeted
Omar M. Khateeb@OmarMKhateeb·Nov 9

Type 2 Diabetes: Shocking results on how this procedure is impacting A1C in diabetics with Bob Haggerty, CEO of Aqua Medical. What if Type 2 diabetes could eventually be treated through an endoscope? I sat down with Bob Haggerty, President and CEO of Aqua Medical @aqua_endoscopy , to unpack one of the more interesting new categories emerging in MedTech: Endoscopic Metabolic Restoration. Aqua is developing an investigational procedure that passes directly through a standard endoscope and uses water vapor to treat the proximal small intestine, an area involved in nutrient sensing and glycemic control. The early clinical signal is what caught my attention. Bob discusses a 66-patient international program where Aqua observed average A1C reductions in the roughly 2.1 to 2.6-point range at one year. But the bigger conversation is about where a procedure like this could fit into diabetes care. We talked about GLP-1s, oral medications, insulin, lifestyle modification, and why the future may not be device versus pharma. For many patients, the better model could be complementary therapies that reduce disease burden from multiple directions. We also went deep on the MedTech side: why Aqua designed the technology to fit through existing endoscopes, how it could integrate into ASC workflow, the economics of chronic diabetes care, its Series B financing, the U.S. clinical pathway, upcoming pivotal work, and what commercialization could eventually look like. A fascinating example of what happens when GI innovation starts moving beyond diagnosis and into metabolic therapy. Episode Breakdown: 00:00 Can Type 2 Diabetes Be Treated Without Lifelong Medication? 01:31 Meet Bob Haggerty, CEO of Aqua Medical 03:10 Bob Haggerty's Journey in Medical Devices and GI Innovation 04:40 Why Type 2 Diabetes Needs Better Treatment Options 05:20 Why Medical Devices Could Reduce Dependence on Medication 06:26 What Is Endoscopic Metabolic Restoration? 07:20 How Treating the Small Intestine Could Improve Blood Sugar Control 08:53 Can Aqua Medical's Treatment Lower HbA1c? 09:34 Clinical Trial Results: Up to 2.6 Percentage Point HbA1c Reduction 10:10 Market Engineering and MedTech Growth 12:42 Can Endoscopic Treatment Work Alongside Diabetes Medication? 13:34 How Does Aqua Medical Compare With GLP-1 Drugs? 14:20 Why GLP-1 Side Effects Create Demand for Other Treatments 15:41 Could Diabetes Treatment Become a Simple Outpatient Procedure? 16:19 How Aqua Medical Fits Into Existing Endoscopy Workflows 17:00 Aqua Medical's Water Vapor Treatment Demonstration 17:39 How Steam Ablation Treats the Small Intestine 19:08 How Does the Procedure Affect Blood Sugar Regulation? 20:00 Understanding HbA1c and the Risks of High Blood Sugar 21:28 The Economic Burden of Type 2 Diabetes 21:51 Could a One-Hour Procedure Reduce Diabetes Healthcare Costs? 23:24 Aqua Medical's Series B Funding and FDA Clinical Trials 24:36 When Could Aqua Medical Receive FDA Approval? 25:39 Could Diabetes Eventually Be Treated With a Procedure? 27:04 The Future of Preventive Metabolic Healthcare 28:08 Why Aqua Medical's Through-the-Scope Design Matters 28:28 Making Diabetes Treatment Easier for GI Physicians 29:51 The Leading Endoscopy Manufacturers: Olympus, Fujifilm and Pentax 31:25 How Aqua Medical Is Improving Its Technology 32:39 Upcoming Clinical Trials and MedTech Conferences 34:11 Final Thoughts and Where to Learn More 35:22 End

35:22
State of Medtech Podcast avatar
State of Medtech Podcast@StateofMedTech·Nov 8

Silicon Valley’s AI Money Is Moving Into the Physical World! Insights from @OmarMKhateeb   Episode 425: Why AI Could Trigger the Next MedTech Investment Boom: a16z State of Markets 2026!

1:10